State Street Corp Updates Anika Therapeutics Stake in SC 13G/A
Ticker: ANIK · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 898437
| Field | Detail |
|---|---|
| Company | Anika Therapeutics, Inc. (ANIK) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still owns Anika stock, no big changes, just a routine update.**
AI Summary
State Street Corp, a major financial institution, filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Anika Therapeutics, Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, showing their continued passive investment in Anika Therapeutics. For investors, this means a large institutional investor maintains a position, which can signal confidence in the company's long-term prospects, but it doesn't suggest any active involvement in management.
Why It Matters
This filing confirms State Street Corp's continued passive ownership in Anika Therapeutics, providing transparency on institutional holdings and potentially influencing investor sentiment.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate risk or significant change in the company's operations or outlook.
Analyst Insight
Investors should note that State Street Corp's continued passive holding in Anika Therapeutics, Inc. suggests a long-term institutional interest, but this filing alone doesn't signal any new catalysts or changes in company direction. It's a routine disclosure of an existing position.
Key Players & Entities
- State Street Corp (company) — the entity filing the SC 13G/A
- Anika Therapeutics, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 22, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934' sections.
Who is the 'subject company' in this filing?
The subject company is Anika Therapeutics, Inc., as identified under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Anika Therapeutics, Inc.'.
Who is the 'filer' of this SC 13G/A?
The filer of this SC 13G/A is State Street Corp, as identified under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: STATE STREET CORP'.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the common stock of Anika Therapeutics, Inc. is 035255108, as stated under 'CUSIP NUMBER: 035255108'.
What was the 'date of event' that triggered this filing?
The date of the event which requires the filing of this statement was December 31, 2023, as indicated by '12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding Anika Therapeutics, Inc. (ANIK).